EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹3,019 Cr
Expense Ratio
0.63%
ISIN
INF740KA1LG1
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
30 Nov 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.80%
+17.55% (Cat Avg.)
3 Years
+20.41%
+18.10% (Cat Avg.)
5 Years
+26.56%
+22.46% (Cat Avg.)
Since Inception
+24.71%
— (Cat Avg.)
Equity | ₹2,993.98 Cr | 99.18% |
Others | ₹24.79 Cr | 0.82% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹325.33 Cr | 10.78% |
Suven Pharmaceuticals Ltd | Equity | ₹286.55 Cr | 9.49% |
Cipla Ltd | Equity | ₹258.22 Cr | 8.55% |
Ipca Laboratories Ltd | Equity | ₹240.9 Cr | 7.98% |
Globus Medical Inc Class A | Equity | ₹168.39 Cr | 5.58% |
Gland Pharma Ltd | Equity | ₹146.61 Cr | 4.86% |
Laurus Labs Ltd | Equity | ₹136.04 Cr | 4.51% |
Alembic Pharmaceuticals Ltd | Equity | ₹132.36 Cr | 4.38% |
Apollo Hospitals Enterprise Ltd | Equity | ₹128.86 Cr | 4.27% |
Sai Life Sciences Ltd | Equity | ₹121.52 Cr | 4.03% |
Illumina Inc | Equity | ₹108.91 Cr | 3.61% |
Vijaya Diagnostic Centre Ltd | Equity | ₹102.64 Cr | 3.40% |
Kovai Medical Center & Hospital Ltd | Equity | ₹85.56 Cr | 2.83% |
Concord Biotech Ltd | Equity | ₹82.31 Cr | 2.73% |
Procter & Gamble Health Ltd | Equity | ₹81.68 Cr | 2.71% |
Pfizer Ltd | Equity | ₹80.35 Cr | 2.66% |
Intuitive Surgical Inc | Equity | ₹79.55 Cr | 2.64% |
Indoco Remedies Ltd | Equity | ₹75.3 Cr | 2.49% |
Unichem Laboratories Ltd | Equity | ₹58.81 Cr | 1.95% |
Narayana Hrudayalaya Ltd | Equity | ₹54.35 Cr | 1.80% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹43.28 Cr | 1.43% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹40.67 Cr | 1.35% |
Emcure Pharmaceuticals Ltd | Equity | ₹36.76 Cr | 1.22% |
Abbott Laboratories | Equity | ₹35.87 Cr | 1.19% |
Aarti Drugs Ltd | Equity | ₹29 Cr | 0.96% |
Alkem Laboratories Ltd | Equity | ₹18.23 Cr | 0.60% |
Global X Genomics & Biotechnology ETF | Mutual Fund - ETF | ₹16.67 Cr | 0.55% |
Net Receivables/Payables | Cash | ₹-15.9 Cr | 0.53% |
Thyrocare Technologies Ltd | Equity | ₹15.57 Cr | 0.52% |
Jupiter Life Line Hospitals Ltd | Equity | ₹15.4 Cr | 0.51% |
Medplus Health Services Ltd | Equity | ₹14.6 Cr | 0.48% |
Laxmi Dental Ltd | Equity | ₹12.48 Cr | 0.41% |
GRAIL Inc | Equity | ₹1.91 Cr | 0.06% |
Large Cap Stocks
19.33%
Mid Cap Stocks
14.29%
Small Cap Stocks
51.52%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,934.05 Cr | 97.19% |
Financial Services | ₹43.28 Cr | 1.43% |
Standard Deviation
This fund
15.95%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.90
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since December 2020
ISIN INF740KA1LG1 | Expense Ratio 0.63% | Exit Load No Charges | Fund Size ₹3,019 Cr | Age 6 years 4 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹1,80,251 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹3,019 Cr
Expense Ratio
0.63%
ISIN
INF740KA1LG1
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
30 Nov 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.80%
+17.55% (Cat Avg.)
3 Years
+20.41%
+18.10% (Cat Avg.)
5 Years
+26.56%
+22.46% (Cat Avg.)
Since Inception
+24.71%
— (Cat Avg.)
Equity | ₹2,993.98 Cr | 99.18% |
Others | ₹24.79 Cr | 0.82% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹325.33 Cr | 10.78% |
Suven Pharmaceuticals Ltd | Equity | ₹286.55 Cr | 9.49% |
Cipla Ltd | Equity | ₹258.22 Cr | 8.55% |
Ipca Laboratories Ltd | Equity | ₹240.9 Cr | 7.98% |
Globus Medical Inc Class A | Equity | ₹168.39 Cr | 5.58% |
Gland Pharma Ltd | Equity | ₹146.61 Cr | 4.86% |
Laurus Labs Ltd | Equity | ₹136.04 Cr | 4.51% |
Alembic Pharmaceuticals Ltd | Equity | ₹132.36 Cr | 4.38% |
Apollo Hospitals Enterprise Ltd | Equity | ₹128.86 Cr | 4.27% |
Sai Life Sciences Ltd | Equity | ₹121.52 Cr | 4.03% |
Illumina Inc | Equity | ₹108.91 Cr | 3.61% |
Vijaya Diagnostic Centre Ltd | Equity | ₹102.64 Cr | 3.40% |
Kovai Medical Center & Hospital Ltd | Equity | ₹85.56 Cr | 2.83% |
Concord Biotech Ltd | Equity | ₹82.31 Cr | 2.73% |
Procter & Gamble Health Ltd | Equity | ₹81.68 Cr | 2.71% |
Pfizer Ltd | Equity | ₹80.35 Cr | 2.66% |
Intuitive Surgical Inc | Equity | ₹79.55 Cr | 2.64% |
Indoco Remedies Ltd | Equity | ₹75.3 Cr | 2.49% |
Unichem Laboratories Ltd | Equity | ₹58.81 Cr | 1.95% |
Narayana Hrudayalaya Ltd | Equity | ₹54.35 Cr | 1.80% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹43.28 Cr | 1.43% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹40.67 Cr | 1.35% |
Emcure Pharmaceuticals Ltd | Equity | ₹36.76 Cr | 1.22% |
Abbott Laboratories | Equity | ₹35.87 Cr | 1.19% |
Aarti Drugs Ltd | Equity | ₹29 Cr | 0.96% |
Alkem Laboratories Ltd | Equity | ₹18.23 Cr | 0.60% |
Global X Genomics & Biotechnology ETF | Mutual Fund - ETF | ₹16.67 Cr | 0.55% |
Net Receivables/Payables | Cash | ₹-15.9 Cr | 0.53% |
Thyrocare Technologies Ltd | Equity | ₹15.57 Cr | 0.52% |
Jupiter Life Line Hospitals Ltd | Equity | ₹15.4 Cr | 0.51% |
Medplus Health Services Ltd | Equity | ₹14.6 Cr | 0.48% |
Laxmi Dental Ltd | Equity | ₹12.48 Cr | 0.41% |
GRAIL Inc | Equity | ₹1.91 Cr | 0.06% |
Large Cap Stocks
19.33%
Mid Cap Stocks
14.29%
Small Cap Stocks
51.52%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,934.05 Cr | 97.19% |
Financial Services | ₹43.28 Cr | 1.43% |
Standard Deviation
This fund
15.95%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.90
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since December 2020
ISIN INF740KA1LG1 | Expense Ratio 0.63% | Exit Load No Charges | Fund Size ₹3,019 Cr | Age 6 years 4 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹1,80,251 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments